Affiliated Hospital of Guilin Medical University
桂林医学院附属医院
Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Affiliated Hospital of Guilin Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌35 papers led
- Hepatocellular carcinoma肝细胞癌66 papers led1 open trial led
- Chordoma脊索瘤1 paper led
- Osteosarcoma骨肉瘤3 papers led
- Neuroblastoma神经母细胞瘤3 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
- Beta thalassaemiaβ 地中海贫血3 papers led
- Hepatic echinococcosis肝包虫病2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Behçet disease白塞病0 papers led
- IgA nephropathyIgA 肾病1 paper led
Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 35 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.5%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Guilin for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Phase
- Phase 1/Phase 2
- Started
- 2025-11
- Registry
- NCT07258979
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen
- RecruitingEffect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05892354
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou
- RecruitingInduction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2022-11
- Registry
- NCT05527470
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuilin, Wuzhou
- RecruitingConcurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Phase
- N/A
- Started
- 2022-12
- Registry
- NCT05717790
Age 18 years to 70 years (registered criteria)
Led by Fourth Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuangzhou, Guilin, Liuzhou, Wuzhou, Zhongshan
- Not yet recruitingIvonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07064902
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 2 listed hospitals as study sitesGuangzhou, Guilin, Xiamen
- Not yet recruitingImpacted Tooth Management and Osteoradionecrosis Risk in NPC
- Phase
- N/A
- Started
- 2026-08
- Registry
- NCT07764887
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Guangxi Medical University; 6 listed hospitals as study sitesGuilin, Liuzhou, Nanning, Wuzhou, Zhongshan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led35
- Rhamnocitrin induces apoptosis of human nasopharyngeal carcinoma by inhibiting IGF-1R signaling pathway in vitro.
- Integrative analysis of taurine metabolism-related genes prognostic signature with immunotherapy and identification of ABCB1 and GORASP1 as key genes in nasopharyngeal carcinoma.
- YTHDF2 enhances proliferation and metastasis of nasopharyngeal carcinoma by mediating m6A modification in destabilizing FOXO1 mRNA.
- Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.
- Influence of COVID-19 Vaccination on Treatment-Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma.
- Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region.
- Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis.
- Interrogating ABCC1 and CASP1 as key players in epigallocatechin gallate's action against radiotherapy-resistant nasopharyngeal carcinoma.
- Multi-Omics Exploration of the Mechanism of Curcumol to Reduce Invasion and Metastasis of Nasopharyngeal Carcinoma by Inhibiting NCL/EBNA1-Mediated UBE2C Upregulation.
- Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma.
- Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma-Reply.
- Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
- An individualized immune prognostic signature in nasopharyngeal carcinoma.
- Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.
- 18F-NaF uptake in skull-base bone as a predictor of treatment response in advanced nasopharyngeal carcinoma.
- Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.
- Building Practical Risk Prediction Models for Nasopharyngeal Carcinoma Screening with Patient Graph Analysis and Machine Learning.
- Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
- Clinical Significance of Serum Iron Metabolism-Related Markers in Patients with Nasopharyngeal Carcinoma.
- RNA-binding domain 2 of nucleolin is important for the autophagy induction of curcumol in nasopharyngeal carcinoma cells.
- Aloe-emodin targets multiple signaling pathways by blocking ubiquitin-mediated degradation of DUSP1 in nasopharyngeal carcinoma cells.
- Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.
- MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.
- In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin, an anti-cancer compound.
- Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.
- Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro.
- Pentagalloylglucose suppresses the growth and migration of human nasopharyngeal cancer cells via the GSK3β/β-catenin pathway in vitro and in vivo.
- Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
- Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.
- Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
- Methylation-associated silencing of miR-9-1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2.
- Exosomes in nasopharyngeal carcinoma.
- Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles.
- Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.
- Curcumol simultaneously induces both apoptosis and autophagy in human nasopharyngeal carcinoma cells.
All its trials on ClinicalTrials.gov, any status13
- Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
- Impacted Tooth Management and Osteoradionecrosis Risk in NPC
- Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
- Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma
- Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
- ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
More papers found outside PubMed (not counted)5
- Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.
- An Integrated Analysis of RNA Sequencing and Molecular Docking Reveal EIF2AK2, IFIT1, and STAT1 as Key Targets of EGCG in Nasopharyngeal Carcinoma
- Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.
- Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation
- Abstract 5128: Identification and characterization of nasopharyngeal carcinoma prognostic subtypes based on a circRNA classifier: Implications of stratified treatment
Cancer
Hepatocellular carcinoma
肝细胞癌Led 66 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
1 hospital in Guilin for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
- Phase
- Not given
- Started
- 2025-01
- Registry
- NCT07141056
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led66
- Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis-Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment.
- Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma.
- Exploring SLC25A42 as a Radiogenomic Marker from the Perioperative Stage to Chemotherapy in Hepatitis-Related Hepatocellular Carcinoma.
- USP7-DDX5-FASN axis drives fatty acid metabolism and supports hepatocellular carcinoma progression.
- Diagnostic performance of LR-5 based on hypointensity on Gd-EOB-DTPA-enhanced MRI in the hepatobiliary phase for sHCC using LI-RADS v2018 criteria.
- The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.
- Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome.
- Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma.
- NDUFAB1 promotes hepatocellular carcinoma progression by disrupting mitochondrial homeostasis and mitophagy pathway.
- Dihydroartemisinin alleviates diethylnitrosamine-induced hepatocarcinogenesis by targeting a novel MAZ/TRIM50 axis.
- MOF-Mediated Aloe-Emodin Delivery Enhances Hepatocellular Carcinoma Immunotherapy via Pyroptosis and Immunosuppressant Synergy.
- Hypericin Nanoparticles-Associated Photodynamic Therapy Modulates the Biological Behavior of Hepatocellular Carcinoma by SERPINE1.
- Casein kinase 1 family member CSNK1E can regulate proliferation and migration in hepatocellular carcinoma.
- MAZ-mediated N6-methyladenosine modification of ZEB1 promotes hepatocellular carcinoma progression by regulating METTL3.
- Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.
- Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism.
- A clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.
- EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.
- Bioinformatics identification of shared signaling pathways and core targets linking Benzo[a]pyrene exposure to HCC progression.
- Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.
- SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.
- Radiomics model based on contrast-enhanced computed tomography imaging for early recurrence monitoring after radical resection of AFP-negative hepatocellular carcinoma.
- Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway.
- Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.
- The Combination of Gd-EOB-DTPA Enhanced T1 Mapping with Apparent Diffusion Coefficient could Improve the Diagnostic Efficacy of Hepatocellular Carcinoma Grading.
- Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis.
- A Novel lncRNA lncRNA-4045 Promotes the Progression of Hepatocellular Carcinoma by Affecting the Expression of AKR1B10.
- GCF2 mediates nicotine-induced cancer stemness and progression in hepatocellular carcinoma.
- Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV
- REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.
- Iron-Based Nanoplatforms Achieve Hepatocellular Carcinoma Regression Through a Cascade of Effects.
- Hepatic infarction occurred after 125I particle stent treatment for hepatocellular carcinoma with portal vein tumor thrombus: A case report.
- A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma.
- The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
- ZBTB34 is a hepatocellular carcinoma-associated protein with a monopartite nuclear localization signal.
- Integrated network findings reveal ubiquitin-specific protease 44 overexpression suppresses tumorigenicity of liver cancer.
- Prognostic Significance of ZP3 in Hepatocellular Carcinoma.
- Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.
- Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.
- Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.
- Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation.
- The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
- Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.
- Nomogram for predicting severe abdominal pain after initial conventional transarterial chemoembolisation for hepatocellular carcinoma: a retrospective study.
- Radiomics model based on contrast-enhanced computed tomography to predict early recurrence in patients with hepatocellular carcinoma after radical resection.
- Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma.
- Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
- S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression.
- Exosomal miR-628-5p from M1 polarized macrophages hinders m6A modification of circFUT8 to suppress hepatocellular carcinoma progression.
- Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro.
- G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.
- Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy.
- Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway.
- hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.
- Circ_0036412 affects the proliferation and cell cycle of hepatocellular carcinoma via hedgehog signaling pathway.
- Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.
- Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease.
- Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection.
- AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study.
- RNA sequencing identifies two novel liver-specific long noncoding RNAs with potential diagnostic value in hepatocellular carcinoma.
- A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
- CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma.
- Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.
- Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization.
- Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.
- Anti-hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro.
Chinese-language papers (not in the count)2
- [VIPR1 promoter methylation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro].
- [miR-152 inhibits the epithelial-mesenchymal transition and renin-angiotensin system of human hepatocellular carcinoma cells by down-regulating AGTR1].
All its trials on ClinicalTrials.gov, any status3
Cancer
Chordoma
脊索瘤Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Guilin for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.
- Anti-neoplastic characteristics and potential targets of calycosin against bisphenol A-related osteosarcoma: bioinformatics analysis.
- microRNA-377-3p inhibits osteosarcoma progression by targeting CUL1 and regulating Wnt/β-catenin signaling pathway.
Chinese-language papers (not in the count)1
Cancer
Neuroblastoma
神经母细胞瘤Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Organophosphorus flame retardant TDCPP induces neurotoxicity via mitophagy-related ferroptosis in vivo and in vitro.
- Circ_0003611 regulates apoptosis and oxidative stress injury of Alzheimer's disease via miR-383-5p/KIF1B axis.
- Inhibition of the TLR/NF-κB Signaling Pathway and Improvement of Autophagy Mediates Neuroprotective Effects of Plumbagin in Parkinson's Disease.
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCD38 Targeted -PET/ CT for Multiple Myeloma
- Phase
- N/A
- Started
- 2026-07
- Registry
- NCT07782944
Age 18 years to Not stated (registered criteria)
Led by Affiliated Hospital of Guilin Medical UniversityGuilin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.
- Classification of symptom subtypes in patients with multiple myeloma during treatment: a cross-sectional survey study in China.
- Hypoxia-Immune-Related Gene SLC19A1 Serves as a Potential Biomarker for Prognosis in Multiple Myeloma.
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 3 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Guilin for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- A sample-in- result -out microfluidic system for β-thalassemia diagnostics via direct whole blood PCR-reverse dot blot.
- Compound heterozygosity for Southeast Asian hereditary persistence of fetal hemoglobin and β0-thalassemia results in thalassemia intermedia: Pedigree analysis and genetic research in a family from South China. A case report.
- Hb New York, preliminary results concerning the hematologic characteristics and the effects on thalassemia.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)3
- Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.
- Thalidomide has a significant effect in patients with thalassemia intermedia.
- A Pilot Study of Noninvasive Prenatal Diagnosis of Alpha- and Beta-Thalassemia with Target Capture Sequencing of Cell-Free Fetal DNA in Maternal Blood.
Other diseases
Hepatic echinococcosis
肝包虫病Led 2 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 1.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Guilin for Behçet disease149 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Guilin for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
Getting in touch
Name card to show staff or a driver
桂林医学院附属医院
Affiliated Hospital of Guilin Medical University
桂林
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Guilin Medical University; Second Affiliated Hospital of Guilin Medical University; Guilin Medical University Affiliated Hospital; Affiliated Hospital of Guilin Medical College; First Affiliated Hospital of Guilin Medical University; College of International Education of Guilin Medical University